Company Update: Merck & Co Inc (NYSE:MRK) – Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer

[Business Wire] – Eisai Co., Ltd. and Merck , known as MSD outside the U.S. and Canada, through a subsidiary, announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy . . . → Read More: Company Update: Merck & Co Inc (NYSE:MRK) – Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer Similar Articles: Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Present at the 35th Annual Cowen Health Care Conference Company Update (NYSE:LLY): Lilly to test combinations with Merck, Bristol-Myers’ cancer drugs Stock Update: Merck & Co Inc (NYSE:MRK) – Merck, Bristol heat up immunotherapy race in lung cancer